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The PPE Protein Rv1196 of Mycobacterium tuberculosis
Exploits the TLR2 Signaling in Macrophages Eliciting an
Anti-Inﬂammatory Response by Producing IL-10
S. Mukhopadhyay ∗, S. Nair, S.C. Mande, S.E. Hasnain
Centre for DNA Fingerprinting and Diagnostics, Hyderabad,
India
Introduction: Though PE and PPE families have been
thought to play important roles in mycobacterial pathogen-
esis from an antigenic as well as immunological view point,
there has not been much information available regarding
their physiological relevance, more so in the light of the
fact that mycobacteria have been highly successful in devis-
ing strategies of immune evasion. One of the PPE proteins,
Rv1196 (PPE18 or mtb39a) was found to be expressed dur-
ing infection and present exclusively in M. tuberculosis and
M. bovis BCG but not in other mycobacterial species. Fur-
ther, the microarray studies indicate that Rv1196 is one of
the proteins involved in maintaining long term survival of
M. tuberculosis within the host. Since Th2 plays an impor-
tant role in activating M. tuberculosis pathogenesis, we
have evaluated the role of Rv1196 protein to interact with
macrophage and affect the Th2 balance.
Method: Cytokine induction was measured by
enzyme immunoassay (EIA). Interacting receptor on
macrophages were identiﬁed by ﬂow cytometry and co-
immunoprecipitation assay using speciﬁc antibody. The
p38 MAPK and ERK 1/2 and JNK signaling was examined by
Western blotting and ﬂow cytometry
Results: We demonstrate that the PPE protein, Rv1196
stimulates macrophages to secrete interleukin (IL)-10
cytokine, which favors a Th2 T-cell response congenial for
mycobacterial survival. However, it does not signiﬁcantly
affect the production of inﬂammatory cytokines like IL-12,
TNF- as well as nitric oxide production. IL-10 induction
was found to be dependent on speciﬁc interaction of Rv1196
protein to the toll-like receptor (TLR) 2 on membrane. We
found that an early and sustained activation of p38 MAPK
(but not ERK 1/2 and JNK) downstream of TLR2 was critical
for triggering of IL-10 by Rv1196.
Conclusion: Our data suggest a unique role of the M.
tuberculosis PPE protein in eliciting an anti-Th1 response
critical for survival of the bacteria.
doi:10.1016/j.ijid.2008.05.1351
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BCG Vaccine Reaction in Infants
S. Raﬁee Tabatabaei ∗, S. Mohebatti, H. Behbod
Pediatric Infectious Research Center, Tehran, Iran (Islamic
Republic of)
B.C.G vaccine with over 80 years antiquity is still themost
used vaccine around the world. Since In 1993, WHO declared
tuberculosis a global emergency, reﬂecting the magnitude
of the concern about the TB epidemic. Immunization of
infants with Bacille Calmette-Guérin vaccine (BCG) can pro-
tect against TB meningitis and other severe forms of TB in
children less than ﬁve years old. BCG vaccine is not rec-
ommended after 12 months of age because the protection
provided is variable and less certain. On the average, 83%
of children around the world received this vaccine at birth
in 2005. Immunity induction and the rate of effectiveness
of this vaccine was reported differently between 2—83% in
various studies.
This study was done for evaluating the effect of B.C.G
vaccine in infancy period. The tuberculin skin test is the
only practical tool for determining the response to BCG
vaccination, but the diameter of the skin test following
immunization is not a good predictor of protection against
Mycobacterium tuberculosis disease.
This study was a cross-sectional study in 794 infant that
born in Taleghani hospital in Arak city during 6 months. After
B. C. G vaccination at birth, in 3 months infants (∼90 days)
the establish scar diameter and tuberculin test with 5 units
has been measured by a trained person. B.C.G scar diameter
in 96% of cases was equal or more than 3mm. (scar posi-
tive) and 4% less than 3mm. (scar negative). Response to
tuberculin test has been negative (<5mm.), in 309 persons
(39%), suspected or vicinal positive (between 5—9mm.) in
436 persons (55%) and positive (≥10mm) in 49 persons (6%).
We found that scar negative cases were only in two groups
who had induration less than 5mm. (n = 26) and between
5—9mm. (n = 5). We did not have any scar negative cases in
third group (≥10mm.).
In addition, we did not see any local reaction and com-
plication at the site of BCG vaccination or development of
regional lymphadenopathy.
The present study concludes that about 96 percent
infants have successful BCG vaccination response (scar posi-
tive). There has been correlation between the size of B.C.G
scar and the severity of indurations of skin test. However,
some evidences in abortive reactors and positive in vitro
leucocyte migration inhibition test (LMIT) in babies with
scar failure strongly suggest that these infants may have
developed immunity to BCG. Therefore, there is a need to
redeﬁne the criteria for revaccination in abortive reactors
who show preliminary response stages but do not develop a
scar.
doi:10.1016/j.ijid.2008.05.1352
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Chemokine Receptor-Mediated Delivery of Mycobacterial
MPT51 Protein Efﬁciently Induces Antigen Speciﬁc T-Cell
Responses
M. Uchijima, T. Nagata, Y. Koide ∗
Hamamatsu University School of Medicine, Hamamatsu,
Japan
Background:Mycobacterium tuberculosis, primary agent
of tuberculosis (TB), is responsible for the three million
deaths annually worldwide. The only TB vaccine cur-
rently available is the attenuated M. bovis strain bacillus
Calmette-Guerin (BCG) which has been reported to have a
variable protective efﬁciency. The emergence of multi-drug-
resistant strains of M.tuberculosis has given urgency to the
need for novel agents and development of more effective
vaccines.
